June 15, 2020 / 10:43 AM / 21 days ago

BRIEF-Xeris Announces Results From Outpatient Stage Of Phase 2 Study Of Developmental Gvoke Ready-To-Use Micro Glucagon

June 15 (Reuters) - Xeris Pharmaceuticals Inc:

* XERIS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE OUTPATIENT STAGE OF A PHASE 2 STUDY OF ITS DEVELOPMENTAL GVOKE READY-TO-USE (RTU) MICRO™ GLUCAGON IN ADULTS AT RISK OF HYPOGLYCEMIA DURING AND AFTER AEROBIC EXERCISE

* XERIS PHARMACEUTICALS INC - STUDY ACHIEVED ALL PRIMARY OBJECTIVES

* XERIS PHARMACEUTICALS INC - A MICRO DOSE OF GVOKE RTU MICRO DEMONSTRATED SAFETY AND TOLERABILITY PROFILE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below